<DOC>
	<DOCNO>NCT00232726</DOCNO>
	<brief_summary>Previously untreated patient malignant melanoma receive new chemotherapy drug currently development . CP-4055 give intravenously day 1-5 every four week complete response disease progression .</brief_summary>
	<brief_title>Clinical Study Previously Untreated Patients With Malignant Melanoma</brief_title>
	<detailed_description>This international multicentre phase II clinical study conduct USA Europe . Previously untreated patient 18 year , metastatic malignant melanoma eligible inclusion fulfil inclusion- exclusion criterion . 16 42 patient enrol Pittsburgh USA , Lund Sweden Oslo Norway . The new development drug CP-4055 administer five consecutive day ( Day 1 5 ) 4 week schedule ( one cycle ) . The dose 200 mg/m2/day . A patient continue treatment complete response ( ) withdraw Clinical Study disease progression , unacceptable toxicity reason describe clinical study protocol . Efficacy assess baseline end every second cycle CT MRI . Safety assessment do visit . Blood sample take haematological biochemical parameter assess safety . Any adverse event record report . The clinical study approve relevant Independent Ethical Committees/Institutional Review Boards Concerned Regulatory Authority appropriate . It conduct accord ICH Good Clinical Practice , Declaration Helsinki , applicable national law regulation . Patients give additional consent two additional , mandatory , procedure perform : - Biopsy ( tissue sample ) particular tumour ( take baseline identification tumour gene ) - Serum sample ( blood drawn baseline end cycle 2 protein sequence analyse , proteomics )</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Patients histologically cytologically confirm stage IV unresectable stage III nonocular malignant melanoma undergone prior chemotherapy treatment melanoma ( chemotherapynaïve ) Measurable disease accord Response Criteria Solid Tumours ( RECIST ) Performance Status 0 – 2 accord ECOG ( Eastern Cooperative Oncology Group ) Performance Status Age 18 year Life expectancy &gt; 3 month Signed informed consent Adequate haematological biological function : Bone marrow function : 1 . Neutrophils ≥ 1.5 x 10^9/L 2 . Platelets ≥ 100 x 10^9/L 3 . Hemoglobin ( Hb ) ≥ 10 g/dL Hepatic function : 1 . AST/ALT ≤ 2.5 time institutional upper limit normal ( ULN ) . If liver metastasis , ≤ 5 time institutional ULN . 2 . Serum bilirubin alkaline phosphatase ≤ 1.5 time institutional ULN Renal function : Creatinine ≤ 1.5 time institutional ULN Known brain metastasis Diagnosis ocular malignant melanoma Radiotherapy 30 % bone marrow Participation another therapeutic clinical study within 30 day enrolment clinical study Prior immunotherapy and/or chemotherapy treatment melanoma Requirement concomitant treatment nonpermitted medication : Alternative drug High dos vitamin History allergic reaction AraC egg Presence serious concomitant systemic disorder incompatible clinical study ( e.g . uncontrolled intercurrent illness include ongoing active infection ) Presence significant central nervous system psychiatric disorder ( ) would hamper patient ’ compliance Pregnancy , breastfeeding , absence adequate contraception male female fertile patient Known positive status HIV and/or hepatitis B C Drug and/or alcohol abuse Any reason , Investigator ’ opinion , patient participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Malignant melanoma</keyword>
	<keyword>CP-4055</keyword>
	<keyword>Chemotherapy-naïve patient</keyword>
	<keyword>Phase II</keyword>
	<keyword>Chemotherapy-naive patient</keyword>
	<keyword>Metastatic malignant melanoma</keyword>
</DOC>